Effects of oral administration of furosemide and torsemide in healthy dogs

American Journal of Veterinary Research

Volumn 68, Issue 10, 2007, Pages 1058-1063

  Hori, Yasutomo ^a   Takusagawa, Fumihiko ^a   Ikadai, Hiromi ^a   Uechi, Masami ^b   Hoshi, Fumio ^a   Higuchi, Sei Ichi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CREATININE; FUROSEMIDE; LOOP DIURETIC AGENT; PLACEBO; TORASEMIDE; UREA;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BIFIDOBACTERIUM; BREEDING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIURETIC ACTIVITY; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; GRAVITY; HISTOPATHOLOGY; LONG TERM EXPOSURE; MALE; NONHUMAN; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PROTEINS; BLOOD UREA NITROGEN; BODY WEIGHT; CREATININE; DIURETICS; DOGS; FEMALE; FUROSEMIDE; HEMATOCRIT; MALE; PLACEBOS; SULFONAMIDES; URINE;

ANIMALIA; BIFIDOBACTERIUM; CANIS FAMILIARIS;

EID: 35448958560     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.10.1058     Document Type: Article

References (34)

1. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-2784.
2. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004;109:1680-1685.
3. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol 1999;19:581-597.
4. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy (Erratum published in Circulation 2002;106:1743). Circulation 2002;105:1348-1353.
5. Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000;2:305-313.
6. Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf 1996;14:104-120.
7. Delarge J. Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide. Arzneimittelforschung 1988;38:144-150.
8. Tsutamoto T, Sakai H, Wada A, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004;44:2252-2253.
9. Fowler SF, Murray KM. Torsemide: a new loop diuretic. Am J Health Syst Pharm 1995;52:1771-1780.
10. Risler T, Kramer B, Muller GA. The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide. Drugs 1991;41:69-79.
11. Russo D, Memoli B, Andreucci VE. The place of loop diuretics in the treatment of acute and chronic renal failure. Clin Nephrol 1992;38:S69-S73.
12. Cosin J, Diez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study (Erratum published in Eur J Heart Fail 2002;4:667). Eur J Heart Fail 2002;4:507-513.
13. Uechi M, Matsuoka M, Kuwajima E, et al. The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. J Vet Med Sci 2003;65:1057-1061.
14. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001;111:513-520.
15. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-2035.
16. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-2565.
17. Nishikawa N, Yamamoto K, Sakata Y, et al. Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy. Circ J 2005;69:1394-1400.
18. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales lnvestigators (Erratum published in Circulation 2001;103:476). Circulation 2000;102:2700-2706.
19. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
20. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-820.
21. Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006;20:1546-1548.
22. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.
23. Cataliotti A, Boerrigter G, Chen HH, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 2002;105:639-644.
24. Fett DL, Cavero PG, Burnett JC Jr. Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure. J Am Soc Nephrol 1993;4:162-167.
25. Abdallah JG, Schrier RW, Edelstein C, et al. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 2001;12:1335-1341.
26. Kim GH, Na KY, Kim SY, et al. Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant 2003;18:1505-1511.
27. Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595-605.
28. + transporter abundances in response to chronic thiazide or loop diuretic treatment in rats. Am J Physiol Renal Physiol 2003;284:F133-F143.
29. Uchida T, Ohtaki Y, Kido H, et al. Diuretic profile of a novel loop diuretic torasemide in rats and dogs. Drugs Exp Clin Res 1991;17:293-298.
30. Blose JS, Adams KF Jr, Patterson JH. Torsemide: a pyridine-sulfonylurea loop diuretic. Ann Pharmacother 1995;29:396-402.
31. Dubourg L, Mosig D, Drukker A, et al. Torasemide is an effective diuretic in the newborn rabbit. Pediatr Nephrol 2000;14:476-479.
32. Sogame Y, Okano K, Hayashi K, et al. Urinary excretion profile of torasemide and its diuretic action in dogs. J Pharm Pharmacol 1996;48:375-379.
33. Uchida T, Hayashi K, Kido H, et al. Diuretic action of the novel loop diuretic torasemide in the presence of angiotensin II or endothelin-1 in anaesthetized dogs. J Pharm Pharmacol 1992;44:39-43.
34. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991;205:145-150.